Neoadjuvant therapy for uveal melanoma of the eye
Part of Cancer, Eyes & vision clinical trials.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with uveal melanoma starting in the choroid or ciliary body (not the iris).
- Your tumor is thicker than 4 millimeters.
- You are in good overall health (able to perform daily activities).
- You have not been previously treated with a PKC inhibitor.
- Your cancer has not spread to other parts of the body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This trial tests a drug called darovasertib given before standard surgery for primary uveal melanoma (a type of eye cancer that hasn't spread). The goal is to see if the drug can shrink the tumor and improve outcomes.
This trial provides access to tebentafusp, a treatment for advanced melanoma of the eye that cannot be removed by surgery. It may help control the disease.
This early-phase study tests whether melphalan can be used to reduce (shrink) a type of eye cancer called choroidal melanoma before additional treatment. It may help by controlling tumor size while doctors closely monitor the eye and outcomes.
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.